KBP Biosciences Is Successfully Selected into the “Raffles Family Office · Hurun China Cheetahs 2021” List
Jan 30, 2022

PRINCETON, N.J., 30 January 2022 -- KBP Biosciences Co., Ltd. (“KBP Biosciences” or the “Company”), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced it is successfully selected into the “Raffles Family Office · Hurun China Cheetahs 2021” List which is co-released by Hurun Research Institute and leading multi-family office Raffles Family Office recently.

image

Hurun Research Institute, has selected 222 companies into the “Raffles Family Office · Hurun China Cheetahs 2021” List this year, in association with leading multi-family office Raffles Family Office. This list includes a list of companies which are set up after the year 2000 that are most likely to ‘go unicorn’ within five years. Cheetahs normally have a valuation of between US$300mn and US$500mn. This is the second edition of the list.

image

(Part of the “Raffles Family Office · Hurun China Cheetahs 2021” List)


KBP Biosciences is a global, clinical-stage biotechnology company, headquartered in Princeton, NJ, focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases with large unmet needs. KBP Biosciences’ pipeline includes 6 novel drug candidates, 3 currently in clinical and preclinical development covering more than 10 indications. CLARION-CKD, the Phase 3 clinical trial of KBP-5074, with the first indication of advanced CKD and uncontrolled hypertension, is being conducted globally.


“KBP Biosciences has been recognized by the Hurun Research Institute for two consecutive years, which is undoubtedly an affirmation of KBP's rapid development and bright future. We will continue to forge ahead in the direction of solving the global huge unmet clinical needs” stated Zhenhua Huang, Chairman and Founder of KBP Biosciences.


About “Raffles Family Office · Hurun China Cheetahs 2021” 

Hurun Research Institute, in partnership with leading multi-family office Raffles Family Office, released the Raffles Family Office · Hurun China Cheetahs 2021 on 17 Jan 2022, a list of companies set up after the year 2000 that are most likely to ‘go unicorn’ within five years. Cheetahs normally have a valuation of between US$300mn and US$500mn. This is the second edition of the list. The Hurun Research Institute collected data from nearly 1,500 unlisted companies in emerging industries and selected 222 companies into the “Raffles Family Office · Hurun China Cheetahs 2021” List.


About Hurun Inc.

Established in the UK in 1999, Hurun is a research, media and investments group, promoting entrepreneurship through its lists and research.  Widely regarded as an opinion-leader in the world of business, Hurun generated 6 billion views on the Hurun brand last year. Best-known today for the Hurun Rich List series, telling the stories of the world’s successful entrepreneurs in China, India and the world, Hurun’s two other key series include the Hurun Start-up series and the Hurun 500 series, a ranking of the world’s most valuable companies. The Hurun Start-up series begins with the Hurun U30s, an awards recognizing the most successful entrepreneurs under the age of thirty, and is today in seven countries. Next up are Hurun Cheetahs, Chinese and Indian start-ups with a valuation of between US$300mn to US$500mn, most likely to go unicorn with five years.  Hurun Global Gazelles recognize start-ups with a valuation of US$500mn to US$1bn, most likely to go unicorn within three years. The culmination of the start-up series is the Hurun Global Unicorn Index. (For further information, see www.hurun.net)


About KBP Biosciences

KBP Biosciences is a global, clinical-stage biotechnology company, headquartered in Princeton, NJ, focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases with large unmet needs. KBP Biosciences’ pipeline includes 6 novel drug candidates, 3 currently in clinical and preclinical development covering more than 10 indications. CLARION-CKD, the Phase 3 clinical trial of KBP-5074, with the first indication of advanced CKD and uncontrolled hypertension, is being conducted globally.


About KBP-5074

KBP-5074 is a non-steroidal MRA discovered and developed by KBP Biosciences. KBP-5074 selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors which can produce antihypertensive, renal and cardioprotective effects. At present, three indications of KBP-5074 are planned and under development, including advanced CKD and uncontrolled hypertension, heart failure / CKD progression and dialysis. The first indication of advanced CKD and uncontrolled hypertension is being conducted globally. KBP-5074 has been investigated in nine clinical studies including the BLOCK-CKD Phase 2b study.  KBP-5074 is expected to provide a new treatment option addressing the unmet medical needs of patients with advanced CKD and uncontrolled hypertension.


About Advanced Chronic Kidney Disease (CKD) and Uncontrolled Hypertension

Current estimates of the prevalence of CKD indicate that there are 138 million adults with CKD in China alone. Available MRAs can provide additional blood pressure control in some of these patients, but usually will increase the risk of hyperkalemia. Many patients with stage 3b/4 CKD are at their maximum tolerated dose of anti-hypertensive medications and still have uncontrolled or resistant hypertension. Therefore, there is a huge unmet medical need in these patients. 


For more information about KBP Biosciences, please visit the company website at https://www.kbpbiosciences.com/.


Contacts:

Investor Relations:

ir@kbpbiosciences.com


Public Relations:

pr@kbpbiosciences.com